Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl syndrome mouse model
Bardet-Biedl syndrome (BBS), a ciliopathy characterized by obesity, hyperphagia, and learning deficits, arises from mutations in Bbs genes. Exacerbated symptoms occur with mutations in genes encoding the BBSome, a complex regulating primary cilia function. We investigated the mechanisms underlying BBS-induced obesity using a Bbs5-knockout (Bbs5–/–) mouse model. Bbs5–/– mice were characterized by hyperphagia, learning deficits, […]
GLP-1 Drugs and Liver Screening Took Center Stage at AACE Meeting
(MedPage Today) — At the recent American Association of Clinical Endocrinology (AACE) annual meeting, leaders highlighted major advances in endocrine care, particularly around obesity and metabolic liver disease. In this MedPage Today video…
Lilly Notches ‘Top-Tier’ Weight Loss Results for Phase I Amylin/Tirzepatide Combo
At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were also impressed by the tolerability profile.
Wegovy and Mounjaro might affect how well your contraceptives work—here’s why
Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those trying to lose weight. But a rise in so-called “Ozempic babies” has led the UK’s medicines regulator to issue guidance on their use by women of reproductive age.
Lilly to Offer Highest Doses Of Weight-loss Drug Zepbound on Website
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on… Reuters Health Information